FDA Approves Genvoya to Treat HIV-1 Infection

Share this content:
FDA Approves Genvoya to Treat HIV-1 Infection
FDA Approves Genvoya to Treat HIV-1 Infection

THURSDAY, Nov. 5, 2015 (HealthDay News) -- A new treatment for HIV has been approved by the U.S. Food and Drug Administration. Genvoya -- a tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide -- can be used to treat HIV-1 infection in adults and children 12 and older weighing at least 77 pounds.

Genvoya -- made by California-based Gilead Sciences -- contains a new form of tenofovir not previously approved by the FDA. This new form of tenofovir delivers lower amounts of drug into the bloodstream, but higher amounts within cells where HIV-1 replicates. The approval is based on four clinical trials that included a total of 3,171 patients. The results of the trials showed Genvoya to be effective in reducing viral loads and comparable to other treatments, the FDA said.

The most common side effect associated with Genvoya is nausea. The product carries a Boxed Warning about the possible risk of a build-up of lactic acid in the blood and severe liver problems, both of which can be fatal. The warning also states that Genvoya is not approved to treat chronic hepatitis B infection.

"Today's approval of a fixed-dose combination containing a new form of tenofovir provides another effective, once-daily complete regimen for patients with HIV-1 infection," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »